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Abstract
Background: Myelin protein zero (MPZ) is a critical structural component of myelin in the peripheral nervous system. The
MPZ gene is regulated, in part, by the transcription factors SOX10 and EGR2. Mutations in MPZ, SOX10, and EGR2 have been
implicated in demyelinating peripheral neuropathies, suggesting that components of this transcriptional network are
candidates for harboring disease-causing mutations (or otherwise functional variants) that affect MPZ expression.
Methodology: We utilized a combination of multi-species sequence comparisons, transcription factor-binding site
predictions, targeted human DNA re-sequencing, and in vitro and in vivo enhancer assays to study human non-coding MPZ
variants.
Principal Findings: Our efforts revealed a variant within the first intron of MPZ that resides within a previously described
SOX10 binding site is associated with decreased enhancer activity, and alters binding of nuclear proteins. Additionally, the
genomic segment harboring this variant directs tissue-relevant reporter gene expression in zebrafish.
Conclusions: This is the first reported MPZ variant within a cis-acting transcriptional regulatory element. While we were
unable to implicate this variant in disease onset, our data suggests that similar non-coding sequences should be screened
for mutations in patients with neurological disease. Furthermore, our multi-faceted approach for examining the functional
significance of non-coding variants can be readily generalized to study other loci important for myelin structure and
function.
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Introduction
Myelin protein zero (MPZ) is an integral membrane glycoprotein
and a major structural component of peripheral nervous system
myelin. MPZ has cell-adhesion properties and forms tetramers that
are thought to bind other tetramers on opposing membranes, thus
holding concentric layers of myelin intact [1,2,3,4]. The importance
of MPZ for proper myelination is underscored by the fact that MPZ
protein-coding and splice-site mutations cause demyelinating
Charcot-Marie-Tooth disease type 1B (CMT1B) [5,6,7]; however,
mutations in transcriptional regulatory elements have not been
reported to date. The identification of null MPZ alleles in patients
with CMT1B suggests that there is a threshold in the amount of
MPZ required for proper myelination [8]; in support of this notion,
mice that are heterozygous for an Mpz-knockout allele develop a
late-onset peripheral demyelinating neuropathy [9]. It is thus
reasonable to consider cis-acting regulatory elements as excellent
candidates for harboring mutations that affect MPZ transcription.
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14346The regulation of MPZ transcription involves at least two
previously described regulatory elements: a proximal promoter
and an enhancer located in the first intron [10,11,12]. Two
transcription factors with known roles in MPZ expression are
SRY-box 10 (SOX10) and early growth response 2 (EGR2);
indeed, mutations in each of these genes have been shown to cause
CMT disease [8,13]. Other studies have demonstrated that
SOX10 and EGR2 bind to the intronic enhancer both in vitro
and in vivo, and that mutagenesis of the SOX10-binding sites
within this enhancer reduces binding of these transcription factors
[11,14,15,16,17]. Such findings suggest that variants within these
SOX10- and EGR2-binding sites may affect MPZ transcriptional
regulation. In support of this notion, a CMT-associated mutation
has been identified in a SOX10 binding site at the gap junction
protein beta 1 (GJB1) locus [18,19].
We sought to identify and study MPZ variants within
evolutionarily conserved SOX10- and EGR2-binding sites. In this
study, we report a rare human variant that alters the activity of an
MPZ enhancer, a finding that has implications for understanding
the transcriptional regulation of MPZ and for assessing the
functional significance of non-coding variants within genes
implicated in human inherited neuropathies.
Results
Conserved sequences and transcription factor-binding
sites within MPZ
We used two approaches to identify evolutionarily conserved
sequences [i.e., multi-species conserved sequences (MCSs)] within
the MPZ gene. First, we generated and collected sequences of the
genomic region encompassing MPZ from multiple species,
generated a multi-sequence alignment, and then analyzed that
alignment for highly conserved segments. Second, we examined
this genomic region on the UCSC Human Genome Browser [20],
which contains annotations about evolutionary sequence conser-
vation. These analyses revealed four MCSs of particular interest:
MPZ-MCS1, MPZ-MCS2, MPZ-MCS3, and MPZ-MCS4
(Fig. 1A). Because SOX10 and EGR2 play important roles in
MPZ expression, we computationally searched for predicted
SOX10- and EGR2-binding sites that reside within each MPZ-
MCS (see Methods for details). This analysis revealed a total of 14
SOX10- and four EGR2-binding sites in the four MCSs (Table 1).
For the experiments described below, each MCS tested directly
corresponds to the UCSC Genome Browser coordinates provided
in the second column of Table 1.
Identification of the c.126-1086T.A nucleotide variant in
MPZ-MCS3
As part of a larger effort to screen patients with neurological
disease for genetic variants, we sequenced the above four MCSs (as
well as all MPZ protein-coding regions) in 192 individuals,
including 69 patients diagnosed with demyelinating peripheral
neuropathy. These efforts revealed one novel variant (c.126-
1086T.A) in a heterozygous state within MPZ-MCS3 (which
resides in the first intron of MPZ; see Fig. 1A) in one patient from
our cohort with congenital non-progressive central nervous system
hypomyelination affecting the supratentorial structures, but no
signs of demyelinating peripheral neuropathy (BAB1733; Fig. 1B).
Importantly, this variant resides within a previously-described
SOX10-binding site within MPZ-MCS3 (Fig. 1B, black half-
arrows and red box) [11,16]; dimerized SOX10 proteins are
known to bind to head-to-head SOX10-binding sequences [21].
No other variants in the SOX10- and EGR2-binding sites listed in
Table 1 were identified in our patient cohort.
The c.126-1086T.A variant is not present in the public SNP
database (dbSNP), and we did not detect it in a panel of 514
chromosomes from a North America population. Analysis of
additional family members revealed that c.126-1086T.A was
inherited from the patient’s father. However, the father was not
available for clinical evaluation, therefore we are unable to
conclude whether or not c.126-1086T.A segregates with disease.
Examination of our multi-sequence alignment (Fig. 1C) and that
available at the UCSC Human Genome Browser (Fig. 1D)
revealed that the affected T nucleotide is extensively (although not
fully) conserved among mammalian species. Of note, the two
sources of armadillo sequence differed in the nucleotide at this
position, being either an A (Fig. 1C) or a T (Fig. 1D); this
discrepancy could represent a sequencing error, an alignment
error, or a natural variation of this nucleotide in armadillo. These
findings indicate that c.126-1086T.A is a rare variant within a
non-coding genomic segment that may be important for MPZ
function.
c.126-1086T.A is associated with decreased in vitro
enhancer activity
We tested each of the four conserved non-coding segments at
MPZ (Fig. 1A) for their ability to direct reporter-gene expression
(Fig. 2A). This involved cloning each segment upstream of a
minimal promoter directing luciferase expression (Fig. 2A),
transfecting each into SOX10-positive Schwann (S16) cells, and
assessing luciferase activity as a proxy of reporter gene expression
compared to a control vector with no insert (pE1b). MCS1 and
MCS4 did not display any ability to direct reporter gene
expression. In contrast, MCS2 and MCS3 directed reporter gene
expression in a manner ,90-fold and ,45-fold higher than the
control vector, respectively. Thus, these data confirm the
previously-reported activity of the MPZ promoter (MCS2) and
intronic enhancer (MCS3) in vitro and in vivo [11,14,15,16,17],
further suggesting that these elements are required for MPZ
expression.
To examine the effect of the c.126-1086T.A variant on in vitro
enhancer activity of MPZ-MCS3, we cloned the wild-type and
variant alleles (both forward and reverse orientations) upstream of
a minimal promoter (pE1b) responsible for directing luciferase
expression, transfected the resulting reporter constructs into
cultured Schwann (S16) cells and oligodendrocytes (OliNeu) cells,
and measured the luciferase activity relative to an internal renilla
control. These studies revealed that the wild-type MPZ-MCS3
allele enhances luciferase expression by ,31.5- and ,7.2-fold
(compared to a control reporter-gene construct lacking a cloned
insert) in the forward and reverse orientations in S16 cells,
respectively (Fig. 2B). In contrast, the c.126-1086T.A-containing
MPZ-MCS3 allele enhances luciferase expression by ,12.7- and
,2.7-fold in the forward and reverse orientations in S16 cells,
respectively (Fig. 2B). Thus, the c.126-1086T.A variant is
associated with a 60–62% reduction of in vitro enhancer activity
(depending on the orientation of the fragment in the reporter
construct). Importantly, these data are consistent with previously-
reported analyses on a similar construct with deleted SOX10
binding sites [16]. We also tested MPZ-MCS3 enhancer activity in
OliNeu cells and found similar results as in S16 cells; the c.126-
1086T.A variant is associated with a 32–42% reduction of in vitro
enhancer activity, slightly less than observed in the S16 cells
(Fig. 2C).
To determine the cell-type specificity of MPZ-MCS3, and to test
the responsiveness of the wild-type and c.126-1086T.A alleles to
SOX10, we tested the enhancer activity of each allele in SOX10-
negative mouse motor neuron (MN-1) cells with, or without, co-
Functional MPZ Variant
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e14346Figure 1. Analysis of MCSs in the genomic region encompassing MPZ. (A) Representation of the MPZ gene and its flanking regions from the
UCSC Human Genome Browser. From top to bottom, tracks are shown displaying information about MPZ-MCSs, MPZ exons, overall multi-species
sequence conservation, and pair-wise sequence conservation between human and five other vertebrate species. MPZ-MCS3 within MPZ intron 1 is
indicated by an arrow. (B) Sequence chromatograms for a region within MPZ-MCS3 are shown for an unaffected individual (control) and patient
BAB1733. Two monomeric consensus SOX10-binding sequences in a head-to-head configuration are indicated by red highlights and horizontal
arrows. The position of the c.126-1086T.A variant (heterozygous in the patient) is indicated with a vertical arrow. (C, D) Multi-sequence alignments
of the consensus SOX10-binding sequences within MPZ-MCS3 (highlighted in red) are shown containing sequences from the indicated species, as
generated by MultiPipMaker (C) or available on the UCSC Human Genome Browser (D). The position of c.126-1086T in each alignment is indicated by
a vertical arrow; dots indicate bases that are identical to the human reference sequence and dashes represent gaps within the alignments.
doi:10.1371/journal.pone.0014346.g001
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neither wild-type nor c.126-1086T.A MPZ-MCS3 displayed
significant enhancer potential in SOX10-negative cells. Second,
the addition of 25 to 200 ng of a SOX10 expression construct
dramatically increased enhancer potential (compared to the
similarly-treated pE1b control vector), further suggesting that
SOX10 specifically acts upon MPZ-MCS3. Interestingly, at each
concentration of SOX10 expression construct, the mean value for
the enhancer activity of the c.126-1086T.A allele (Var) was lower
than that for the wild-type (Wt) allele (Fig. 2D); however, none of
these experiments reached statistical significance.
c.126-1086T. A is associated with altered nuclear-
protein binding
SOX10 and EGR2 have previously been shown to bind to
MCS3, and deletion of the SOX10 consensus sequences ablate
SOX10 binding [16]. We used electrophoretic mobility shift assays
(EMSAs) to establish if the c.126-1086T.A variant is associated
with altered binding of nuclear proteins (e.g., transcription factors)
to MPZ-MCS3. Briefly,
32P-labeled double-stranded oligonucleo-
tides (i.e., ‘probes’) containing the SOX10-binding consensus
sequence within MPZ-MCS3 were incubated with nuclear extracts
from S16 cells (pre-incubated with or without unlabeled oligonu-
cleotides (i.e., ‘competitors’)), and then separated on a polyacryl-
amide gel. The probe containing the wild-type sequence appears to
binda single specificnuclear protein,while the probecontaining the
v c.126-1086T.A variant binds an additional nuclear protein
(Fig. 2E). Notably, a competitor probe containing the variant
sequence completely ablates binding of this additional nuclear
protein, while an equivalent amount of the wild-type competitor did
not. From this, we have shown that c.126-1086T.A alters the
binding of nuclear proteins at MPZ-MCS3, potentially contributing
to the reduced enhancer strength we observed in our in vitro studies.
MPZ-MCS3 directs reporter-gene expression in
developing zebrafish embryos
We further studied the function of MPZ-MCS3 in vivo using a
zebrafish model system. We hypothesized that if MPZ-MCS3
contributes to MPZ transcriptional regulatory control, this
sequence interval would likely direct reporter-gene expression in
myelinating cells in vivo. Specifically, this would include central
nervous system oligodendrocytes and peripheral nervous system
Schwann cells. Tol2-harboring transgene constructs containing
either wild-type or c.126-1086T.A human MPZ-MCS3 cloned
upstream of a c-fos minimal promoter and the EGFP gene were
injected into two-celled zebrafish embryos. We selected all
embryos expressing EGFP in mosaic G0 embryos to be raised
and screened for germ-line transmission of the transgene. EGFP
expression was documented at selected developmental time points
(ranging from 24 hpf to 7 dpf) in the offspring of multiple
independent founder transgenic-zebrafish for each construct.
Our analyses revealed strong EGFP expression in the telenceph-
alon, midbrain tegmentum, lenses, and hindbrain (Fig. 3A, C, and
E). At later stages (72 hpf and 7 dpf) expression became less
abundant in the anterior CNS, yet remained present in the
peripheral motor nerves; signal was also evident along the
developing posterior lateral line nerve (arrow heads in Fig. 2C
and E). This pattern largely correlates with endogenous mpz
expression during zebrafish development—mpz is expressed in a
dynamicspatial and temporalfashionfrom earlystages inthelateral
tegmentum, lens vesicles, optic nerves, hindbrain and anterior
spinal cord [22,23,24]. Interestingly, mpz expression in zebrafish has
been reported to be restricted to the CNS during early development
[22,25],whereasthemammalianorthologsarebelievedprimarilyto
be expressed in Schwann cells [26].
In contrast to zebrafish harboring the wild-type enhancer,
transgenic lines carrying c.126-1086T.A MPZ-MCS3 displayed
markedly reduced EGFP expression in the forebrain, midbrain,
and hindbrain (Fig. 3B, D and F), which was dramatically reduced
at 48 hpf. Furthermore, descending motor nerves were not visible
at this or other developmental time points in c.126-1086T.A
MPZ-MCS3 zebrafish. While these differences may be due to the
position of the inserted transgene and/or transgene copy number,
they were observed in two wild-type and two c.126-1086T.AF 1
zebrafish lines and are consistent with the above data showing
decreased enhancer activity and altered nuclear-protein binding
associated with the c.126-1086T.A variant (Fig. 2B-D). Both,
Table 1. Transcription factor-binding sites within MPZ MCSs.
MPZ-MCS MCS Position
1 SOX10-binding Site
1,2 EGR2-binding Site
1
MPZ-MCS1 chr1:159549725-159549930 chr1:159549894-159549898
chr1:159549816-159549820
chr1:159549756-159549760
MPZ-MCS2 chr1:159546302-159547303 chr1:159547247-159547251 chr1:159546546-159546554
chr1:159547231-159547235
chr1:159547177-159547181
chr1:159547044-159547048
chr1:159546979-159546983
chr1:159546648-159546652
chr1:159546573-159546588
MPZ-MCS3 chr1:159544784-159545029 chr1:159544923-159544937 chr1:159544903-159544911
chr1:159544891-159544895 chr1:159544853-159544861
MPZ-MCS4 chr1:159535703-159535928 chr1:159535756-159535760 chr1:159535795-159535803
chr1:159535734-159535738
1Coordinates are from the March 2006 assembly of the human genome sequence at the UCSC Genome Browser.
2Dimeric SOX10-binding sites are indicated in bold.
doi:10.1371/journal.pone.0014346.t001
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medulla oblongata and the spinal cord, potentially corresponding
to the developing oligodendrocytic cells (Fig. 3B, DF and Fig. S1).
In addition, we observed no overlap of reporter expression with
acetylated tubulin (AcT) in the sympathetic nerves and probable
oligodendrocytes in the spinal cord of 7 dpf fish carrying the wild-
type MPZ-MCS3 (Fig. S1), which suggests that cells marked by this
regulatory element are glial. Nevertheless, partial overlap of EGFP
with AcT and mbp was visible in PLL ganglia (Fig. S1). This
EGFP expression is consistent with glia ensheathing neuronal cells,
nevertheless we cannot definitely exclude potential neuronal
activity of the MPZ-MCS3 enhancer.
Discussion
In this study, we show that a naturally-occurring, rare, non-
coding nucleotide variant modulates the activity of an MPZ-
transcriptional enhancer. Specifically, we performed targeted
genomic re-sequencing of a collection of patients with neurological
disease, focusing our attention on predicted SOX10- and EGR2-
binding sites within evolutionarily conserved non-coding regions of
the MPZ gene. These efforts resulted in the identification of a rare
variant (c.126-1086T.A) in a previously described SOX10-
binding site [11,16] in the first intron of MPZ. We characterized
this variant in greater detail using a number of methods, including
human population screening, comparative sequence analysis, in
vitro reporter-gene assays in cultured Schwann and oligodendro-
cyte cells, electromobility shift assays (EMSAs), and in vivo reporter-
gene expression in zebrafish. Our data indicate that the c.126-
1086T.A variant resides at a nucleotide position that is highly
conserved among mammals, is associated with decreased enhancer
activity and altered nuclear-protein binding, and is situated in a
genomic segment that directs reporter-gene expression in relevant
tissues in developing zebrafish.
Figure 2. Functional characterization of the c.126-1086T.A variant in MPZ-MCS3. (A) Genomic segments spanning each MPZ MCS (MPZ-
MCS1, MPZ-MCS2, MPZ-MCS3, and MPZ-MCS4) were tested for their ability to direct luciferase reporter-gene expression in cultured Schwann (S16) cells
comparedtoacontrol vector(pE1b).Errorbarsindicatestandarddeviation. (B) Wild-type(Wt)andc.126-1086T.Avariant(Var)formsofMPZ-MCS3were
tested for their ability to direct luciferase reporter-gene expression in the forward (blue) and reverse (red) orientations in cultured Schwann (S16) cells
compared to a control vector (pE1b). Error bars indicate standard deviation. (C) Similar experiments as described in B were performed with cultured
oligodendrocytes (OliNeu) cells. (D) Wild-type (Wt) and c.126-1086T.A (Var) forms of MPZ-MCS3 were tested for their responsiveness to SOX10 via
luciferase reporter-gene expression in SOX10-negative MN1 cells, in the forward orientation compared to a control vector (pE1b). The amount of SOX10
expression vector co-transfected is shown. Error bars indicate standard deviation and p-values were calculated using the student’s t-test.
(E) Electrophoretic mobility shift analysis (EMSA) of wild-type and c.126-1086T.A alleles. ‘Probes’ (radiolabeled oligonucleotides) and ‘competitors’
(unlabeled oligonucleotides) corresponding to a 25-bp fragment including the wild-type (Wt) and c.126-1086T.A variant-containing (Var) consensus
SOX10-binding sequence in MPZ-MCS3 (see Fig. 1B) were incubated with S16 nuclear extracts and subjected to electrophoresis (see Materials and
Methods). Each assay used the same amount of probe coupled with varying amounts of competitor, as shown (‘none’ indicates no competitor; * and **
indicate a probe to competitor ratio of 1:10 and 1:100, respectively). Arrows denote specific nuclear proteins bound to the probe.
doi:10.1371/journal.pone.0014346.g002
Functional MPZ Variant
PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e14346We were unable to clinically evaluate the transmitting parent
(father) of the patient carrying this variant (BAB1733). Therefore,
the c.126-1086T.A variant was not implicated in disease onset in
humans. Thus, the development of a relevant vertebrate model
(e.g., mouse) harboring c.126-1086T.A MPZ will be necessary to
clarify the potential pathogenic role, if any, of this variant.
However, our findings indicate that it would be prudent to screen
these (as well as other) MPZ non-coding sequences for functional
variants in human populations.
Our in vitro functional studies indicate that the wild-type
genomic segment encompassing the c.126-1086T.A variant
(MPZ-MCS3) directs reporter-gene expression in cultured
Schwann and oligodendrocyte cells, does not display enhancer
activity in SOX10-negative cells, is responsive to SOX10, and is
bound by a nuclear protein—likely SOX10, which has been
shown to bind this region in previous studies [11,16]. Alterna-
tively, c.126-1086T.A decreases enhancer activity in these same
SOX10-positive cells and alters the binding of nuclear proteins.
There are two possible interpretations of these data. First, it is
conceivable the variant weakens the affinity for SOX10 and/or
creates a novel protein binding site that competes with SOX10.
Second, the variant could alter the nature of SOX10:EGR2
protein interactions in the nucleus; however, the fragment
analyzed in EMSA analyses did not contain the EGR2 binding
sequences. In any case, c.126-1086T.A MPZ represents a rare,
functional variant this likely affects MPZ expression in vivo.
The studies we performed in zebrafish revealed that human
MPZ-MCS3 directs reporter-gene expression in the hindbrain and
spinal column in positions consistent with oligodendrocytes. These
data are consistent with the established expression pattern of
zebrafish mpz at 48 hpf and later [22]. Furthermore, human wild-
type MPZ-MCS3 directs reporter-gene expression in distal regions
of the descending spinal motor nerves, lateral line nerve, and
sympathetic chain nerves. These findings are consistent with the
expression of genes in Schwann cells, which myelinate all
peripheral neurons. Interestingly, while MPZ is expressed in
mammalian Schwann cells, mpz expression has not been detected
in zebrafish Schwann cells up to 10 dpf by whole-mount in situ
hybridization [22]. There are numerous possible explanations for
this discrepancy. First, whole-mount in situ hybridization may not
Figure 3. MPZ-MCS3 directs reporter gene expression in relevant tissues in vivo. Wild-type (A, C, and E) and c.126-1086T.A variant (B, D,
and F) containing MPZ-MCS3 were studied for their ability to direct the expression of EGFP in developing zebrafish; expression was analyzed at the
indicated developmental stages; EGFP expression is noted in structures consistent with the hindbrain (Hb), midbrain (Mb), forebrain (Fb), descending
motor neurons (arrows), lateral line (arrow heads), and oligodendrocytes (boxes and inset in F).
doi:10.1371/journal.pone.0014346.g003
Functional MPZ Variant
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cells. Second, mpz may be expressed at a later stage in zebrafish
development, due to gene regulation by other elements (e.g.,
silencers) acting in a concerted fashion with the intron-1 enhancer.
Third, mpz may not be expressed in zebrafish Schwann cells; in
this case, the human wild-type MPZ-MCS3 transgene may direct
expression of EGFP because sox10 is expressed in Schwann cells in
zebrafish by 30–40 hpf [27]. Finally, the discrepancy in expression
patterns between fish and terrestrial vertebrates may be due to the
early, rapid evolution of the myelination process, which is crucial
for vertebrate development. In higher vertebrates, the major
requirement for adhesive molecules in the CNS may be encoded
by other loci [28]. Indeed, this might explain the EGFP expression
observed in glial cells of both the CNS and PNS in our studies
(Figs. 3 and S1)—while the transcriptional vocabulary may be
preserved between human and zebrafish, the tissue-specific
requirements and corresponding expression patterns may differ.
The first intron of MPZ shares little sequence conservation
between mammals and zebrafish (Fig. 1A); indeed, it is not possible
to generate a sequence alignment between mammalian species and
zebrafish in this region (data not shown). This observation is
surprising given that human MPZ-MCS3 is functional in
developing zebrafish. Such a discrepancy has been encountered
with other non-coding genomic segments [29,30], and it has been
proposed that current algorithms for detecting sequence conser-
vation between evolutionarily diverse species are not sufficiently
sensitive to identify all functional non-coding sequences [31].
There are two possible explanations for the surprising lack of
sequence conservation in light of our finding that human MPZ-
MCS3 directs reporter-gene expression in developing zebrafish.
First, there may be functional conservation between the
orthologous regions in mammals and zebrafish, with sequence
conservation falling below a threshold required for computational
detection; it is notable that there are a number of SOX10-binding
consensus sequences within this genomic region in zebrafish (data
not shown). Second, MPZ-MCS3 may be functional in mammals,
but the orthologous region may not be functional in non-
mammalian vertebrates (e.g., zebrafish); thus, MPZ-MCS3 might
be a mammalian lineage-specific transcriptional regulatory
element. Each of these possibilities could be investigated further
by analyzing overlapping segments of the first intron of the
zebrafish mpz gene for enhancer activity in appropriate cell culture
and in vivo model systems.
The complete sequencing of the human genome [32] and the
initial analyses that have subsequently been performed [33] reveal
the complexities of non-coding DNA, including sequence elements
that regulate transcription. The study of functional non-coding
sequences is becoming increasingly relevant for understanding the
genetic basis of human disease. Yet, major challenges remain both
in identifying such sequences and in establishing if variants
residing in such sequences are phenotypically relevant. While we
were unable to implicate the MPZ intronic variant in disease
onset, the experimental pursuits described here attempted to
address the above-mentioned challenges. First, comparative
sequencing coupled with other bioinformatic-based analyses were
used to prioritize the more detailed examination of candidate
functional non-coding sequences. Second, a variant detected in a
human population was studied by both in vitro and in vivo assays in
an attempt to experimentally establish the functional consequences
of such variation. While in vitro reporter-gene assays are relatively
routine, they do not provide broad biological insight into the role
of the non-coding sequences being studied (or of the variants
residing therein). Our use of zebrafish to study the wild-type and
variant forms of MPZ-MCS3 nicely illustrates the value of an
in vivo assay system, particularly since certain mammalian
transcriptional regulatory elements are known to function in
zebrafish. However, the zebrafish system also has limitations, such
as for studying sequences that function in a mammalian- or
human-specific fashion and for capturing quantitative data about
reporter-gene expression. For the latter limitation, developing a
zebrafish system for quantitatively measuring allelic differences in
enhancer activity would be a major step toward improving our
ability to characterize the functional consequences of non-coding
variants and to establish their roles in human disease.
Methods
Ethics Statement
All of the studies performed herein were performed under IRB
and ACUC approval from the National Institutes of Health
(NHGRI), Baylor College of Medicine, and Johns Hopkins
University.
Comparative sequence analysis
Two complementary methods were used to identify multi-species
conserved sequences (MCSs) in the genomic region encompassing
the human MPZ gene. First, MPZ-containing bacterial artificial
chromosomes derived from the following species were isolated and
sequenced as described [34]: lemur (GenBank No. AC157839), dog
(GenBank No. AC158443), cow(GenBank No. AC158441), hedge-
hog (GenBank No. AC157618), and armadillo (GenBank
No. AC157449). Sequences encompassing MPZ in human [Uni-
versity of California at Santa Cruz (UCSC) Human Genome
Browser March 2006 assembly, chr1:159521864-159550790],
mouse (UCSC Mouse Genome Browser August 2005 assembly,
chr1:170969846-171282175), rat (UCSC Rat Genome Browser
June 2003 assembly, chr13:86986762-87476861), and zebrafish
(UCSC Zebrafish Genome Browser July 2007 assembly,
chr2:39940779-40174778) were obtained from the UCSC Genome
Browser (genome.ucsc.edu). All sequences were analyzed using
MultiPipMaker [pipmaker.bx.psu.edu/cgi-bin/multipipmaker [35]
to yield a multi-sequence alignment (in the form of an acgt file),
which was subsequently analyzed using ExactPlus [36] to identify
segmentsatleast5 bplongand100%conservedinatleast6 species.
Second, the UCSC Human Genome Browser (March 2006 build)
was used to identify non-coding regions in and around the MPZ
gene (chr1:159521864-159550790) with a PhastCons score of at
least 350. SOX10- and EGR2-binding sites were identified within
the ExactPlus- and PhastCons-detected MCSs using the PATCH
algorithm of the TRANSFAC database [37]; for this analysis, a
minimum site length of 6 bp (tolerating zero mismatches with
known binding sites) and a lower score boundary of 87.5 were
required.
Patient DNA samples and variant screening
DNA samples were obtained from patients diagnosed with
neurological disease based on an examination by a collaborating
physician. For genetic analyses, genomic DNA was purified from
patient-derived peripheral blood or lymphoblastoid cell lines using
standard procedures. All studies were performed with the approval
of the appropriate Institutional Review Board.
Each genomic region of interest was screened for sequence
variants by PCR amplification and direct sequencing of the
amplified DNA segment. Specifically, oligonucleotide primers
(sequences available upon request) were designed to amplify each
region. PCR assays contained 1.5 mM of each primer, 0.2 mM
dNTPs, 1.5 mM MgCl2, 1 unit AmpliTaq DNA Polymerase
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buffer, and 200 ng of genomic DNA. Thermal cycling consisted of
an initial denaturation for 2 minutes at 93uC, followed by 40 cycles
of 93uC for 10 seconds, 55uC for 5 seconds, and 72uC for 30
seconds. A final incubation at 72uC was then performed for 7
minutes. Following electrophoretic separation on a 1% agarose
gel, the PCR products were excised and purified using the
QIAquick Gel Extraction Kit (Qiagen, Valencia, CA). DNA
sequencing was performed using BigDye terminator chemistry.
Reactions (20 ml total) consisting of 8 ml BigDye mix, 0.5 ml
sequencing primer (at 25 mM), 6.5 ml water, and 5 ml PCR
product (at ,50 ng/ml) were subjected to 30 cycles of 92uC for 20
seconds, 55uC for 10 seconds, and 60uC for 4 minutes.
Subsequently, unincorporated nucleotides were removed using
CentriSep 8 column strips (Princeton Separations, Adelphia, NJ),
and the final products were analyzed on a model 3100 DNA
sequencing instrument (Applied Biosystems, Foster City, CA).
Data were extracted and analyzed using Sequencing Analysis
software (Applied Biosystems), and the resulting sequences were
aligned with Sequencher (GeneCodes, Ann Arbor, MI). Genotyp-
ing for the c.126-1086T.A allele was performed by direct
sequencing of PCR products (as above) amplified from DNA
samples from a North American population [38].
Reporter constructs
Reporter constructs for assaying enhancer activity and gene
expression were generated using Gateway cloning technology
(Invitrogen, Carlsbad, CA). Briefly, PCR primers containing
flanking attB sites (on their 59 ends) were designed to amplify
each MPZ-MCS from human DNA. To obtain both the wild-type
and c.126-1086T.A-containing alleles for the MPZ-MCS3 (see
Results), PCR amplification was performed using a DNA sample
from the heterozygous patient (BAB1733). PCR products
containing each allele were then recombined into the pDONR221
vector (according to the manufacturer’s instructions) to yield
appropriate entry clones; the insert of each selected entry clone
was sequenced to identify a clone containing each allele with no
PCR-induced mutations. Subsequently, plasmid DNA purified
from each entry clone was recombined with either the pLGF-E1b
(for luciferase expression in cultured cells) [36] or pXIG-cfos-
EGFP [for enhanced green fluorescent protein (EGFP) expression
in developing zebrafish embryos [30]] destination vectors
according to the manufacturer’s instructions. Each resulting
reporter construct was analyzed by restriction enzyme digestion
(with BsrGI) to confirm the presence of an appropriately-sized
insert.
Assaying in vitro enhancer activity
Immortalized rat Schwann (S16) cells and mouse motor neurons
(MN1) were cultured in Dulbecco’s Modified Eagle Medium
(DMEM; Invitrogen) supplemented with 10% fetal bovine serum
(FBS; Invitrogen) and 1X glutamine, as previously reported [39].
Immortalized mouse oligodendrocyte (OliNeu) cells were cultured
as previously reported [40]. Cells (5610
4) were placed into each
well of a 96-well culture plate and transfected with luciferase
reporter constructs (see above) using Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA). For each reaction, 0.25 ml Lipofecta-
mine 2000 and 25 ml OptiMEM I minimal growth medium
(Invitrogen) were combined and incubated at room temperature
for 10 minutes. The purified luciferase reporter construct (200 ng)
[or the equivalent volume of water (in the case of DNA-negative
controls)] and 2 ng of purified pCMV-RL vector (a renilla-
expression construct that served as an internal control; Promega,
Madison, WI) were diluted in 25 ml OptiMEM I and then
combined with the Lipofectamine-OptiMEM I mixture. The ,50-
ml reactions were incubated at room temperature for 20 minutes
and then added to a single well of the 96-well culture plate
containing cells. After a 3-hour incubation at 37uC, the medium
was aspirated, and normal growth medium was added. The
SOX10 expression construct was obtained from Origene (Rock-
ville, MD).
Following a 48-hour incubation at 37uC, cells were washed with
1X PBS and lysed at room temperature using 1X Passive Lysis
Buffer (Promega). An aliquot (4 ml) of the resulting cell lysate was
transferred to a white polystyrene 96-well assay plate (Corning
Inc., Corning, NY). Luciferase and renilla activities were measured
using the Dual Luciferase Reporter 1000 Assay System (Promega)
and a model Centro LB 960 luminometer (Berthold Technologies,
Bad Wildbad, Germany). Each experiment was performed at least
16 times. In each case, the ratio of luciferase to renilla activity and
the increase in this ratio over that measured for pLGF-E1b with
no insert (indicated as ‘fold increase in luciferase activity’) were
calculated. The mean (bar heights in Fig. 2) and standard
deviation (error bars in Fig. 2) were determined using standard
calculations.
Assaying nuclear-protein binding
Complementary pairs of oligonucleotides (sequences available
upon request) specific for the genomic DNA encompassing MPZ
intron 1 SOX10-consensus sequence (see Results) were annealed
and end-labeled with [c-
32P]ATP (PerkinElmer, Boston, MA)
using 10 units of T4 polynucleotide kinase (Promega). The
radiolabeled products (probes) were purified using an Illustra
TM
Microspin
TM G-25 column (GE Healthcare, Piscataway, NJ). The
ionizing radiation of each probe was measured using a liquid
scintillation counter (L2 6500, Beckman Coulter, Fullerton, CA).
Nuclear extracts from S16 cells, prepared using a Nuclear
Extraction Kit (Cayman Chemical, Ann Arbor, MI), were
incubated in a 20-ml reaction with or without unlabeled double-
stranded oligonucleotides (competitor) in the presence of DNA-
binding buffer (Promega) for 10 min at room temperature.
Samples were then incubated with the above
32P-labeled probes
(17.5 fmol/sample) for 20 min at room temperature. The DNA/
protein complexes were separated on a 6% TBE DNA
Retardation gel (Invitrogen) at room temperature, dried at 80uC
for 1 hr, and visualized using a Fujifilm FLA-5000 image analyzer
(FujiFilm, Tokyo, Japan).
Gene-expression studies in zebrafish
Zebrafish were raised and bred using standard protocols,
including maintaining staged embryos at 28uC [41,42]. EGFP-
expression constructs (see above) were injected into AB back-
ground G0 embryos (n$200) as described [30,43]. Injected
embryos were evaluated for EGFP expression between 24 hours
post fertilization (hpf) and 7 days post fertilization (dpf). Embryos
showing consistent EGFP expression were selected and allowed to
mature and subsequently crossed, which permitted germline
transmission and better evaluation of EGFP expression. Embryos
were imaged using a Carl Zeiss Lumar V12 Stereo microscope
with AxioVision software (version 4.5).
7dpf embryos were anesthetized with tricaine (10 mg/ml) in
embryo medium [42] and fixed in 4% paraformaldehyde in
phosphate-buffered saline (PBS; pH 7.2) for 2 hours. They were
then rinsed four times in PBST (PBS/0.1% Triton X-100),
incubated in Proteinase K for 1 h at room temperature, washed
565 minutes in PBST, and incubated for 2 hours in blocking
solution (10% goat serum, 1% bovine serum albumin [BSA], in
PBST). Embryos were then incubated overnight at room
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1% goat serum, and incubated overnight at room temperature in
secondary antibody. They were then rinsed 5610 minutes in
PBST and transferred to 50% glycerol in PBS. For primary
antibodies, anti-acetylated tubulin (Sigma) was used at 1:100, anti-
gfp (Invitrogen) was used at 1:2,000. Alexa Fluor 488 and 555
(Invitrogen) were used as secondary antibodies (1:1000).
Supporting Information
Figure S1 MPZ-MCS3 wild-type transgenic zebrafish embryos
(7dpf) stained for EGPF (A-K) and acetylated tubulin (AcT in
B,C,E,F,H, and I) and MBP (K and L). Panels A-C and J-K
display the lateral view at the PLL ganglion region. Panels D-F
represent lateral views showing trunk expression, whereas panels
G-I show sympathetic chain expression from the ventro-lateral
view; anterior is to the left; white arrowheads indicate PLL; white
arrows indicate probable oligodendrocytes and blue arrows point
at cells expressing EGFP but not AcT in the sympathetic chain
nerves.
(9.167 MB TIF)
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